Specific treatment indication
-
It is unknown whether and to what degree trials submitted to the US FDA to support drug approval adhere to NCCN guideline-recommended care in their baseline and surveillance CNS imaging protocols. Objective: We sought to characterize the frequency with which the trials cited in US FDA drug approvals for first line advanced NSCLC between 2015 and 2020 deviated from NCCN guideline-recommended care for baseline and surveillance CNS imaging.
8p vielonmusk 21-01-2022 13 0 Download
-
The catalyst 7.5% NiO/TiO2 and seven samples of NiO/γ-Al2O3 with NiO content from 7.5% to 60% have been obtained and studied. Physico-chemical characteristics of the catalysts were determined by methods of Adsorption (BET), X-ray Diffraction (XRD), TemperatureProgrammed Reduction (TPR) and Hydrogen Pulse Titration. The catalytic properties of the obtained samples were investigated in the reaction of CO methanation at temperatures 180 – 220◦C and mole ratios hydrogen/carbon monoxide 25-100.
16p 12120609 01-06-2020 6 1 Download